Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

• Status: Completed
• Trial end date: 2021-03-12

Summary

About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks. Each three weeks is a cycle. Some factors predict that you may not be cured with R-CHOP-21. The most common ones are:

• Stage - how much DLBCL, PMBL, or FL3B you have

• LDH - a blood chemistry marker; and

• Whether you can do your normal daily activities. (performance status) We think that the best way to cure more patients with poor risk factors is to add new treatment to R-CHOP. You will get different chemotherapy after 4 cycles. This type of treatment is called risk-adapted therapy.

• Phase: Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Columbia University; Genentech, Inc.
• Treatments: Carboplatin; Carmustine; Cyclophosphamide; Etoposide; Etoposide phosphate; Ifosfamide; Isophosphamide mustard; Mitoxantrone; Rituximab